Elevated Expression of CAV1 is Associated with Unfavorable Prognosis of Patients with Breast Cancer Who Undergo Surgery and Neoadjuvant Chemotherapy

Neoadjuvant chemotherapy (NACT), which is standard treatment for locally advanced breast cancer, improves the resectability of patients with early breast cancer and reduces the extent of breast and axillary surgery. Caveolin-1 (CAV1) is implicated in human cancers, although its utility for cancer pr...

Full description

Saved in:
Bibliographic Details
Published in:Cancer management and research 2020-01, Vol.12, p.8887-8892
Main Authors: Ye, Jia-Hui, Shi, Jia-Jun, Yin, Xi, Wu, Hong-Yan, Xu, Xin-Yun, Yao, Yong-Zhong, Zhang, Wei-Jie
Format: Article
Language:English
Subjects:
Adjuvant chemotherapy
Age
Analysis
Autophagy
biomarker
Brain cancer
Breast cancer
Cancer patients
Cancer therapies
cav1
Chemotherapy
clinical outcome
Clinical outcomes
Fibroblasts
ihc
Immunohistochemistry
Medical prognosis
Medical records
Metastasis
Original Research
Patients
Prognosis
Regression analysis
Signal transduction
Smooth muscle
Surgery
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neoadjuvant chemotherapy (NACT), which is standard treatment for locally advanced breast cancer, improves the resectability of patients with early breast cancer and reduces the extent of breast and axillary surgery. Caveolin-1 (CAV1) is implicated in human cancers, although its utility for cancer prognosis is unknown. Here, we investigated the expression of CAV1 in breast cancer tissues to evaluate its prognostic significance on patients with breast cancer administered NACT. CAV1 expression in 80 breast cancer tissue samples was evaluated using immunohistochemistry (IHC). The association between CAV1 levels and clinical factors was analyzed using the chi-square test and that between CAV1 and prognosis was evaluated using multivariate Cox regression and Kaplan-Meier analyses. High levels of CAV1 were significantly associated with survival, and patients with overexpression of CAV1 had a poor prognosis. Adjusted multivariate Cox regression analyses revealed that a high level of CAV1 expression was an independent, significant prognostic factor for patients with breast cancer treated with NACT. Overexpression of CAV1 in patients with breast cancer administered NACT was associated with shorter disease-free survival and overall survival. Therefore, high levels of CAV1 may serve as a prognostic biomarker for such patients.
ISSN:1179-1322
1179-1322
DOI:10.2147/CMAR.S264673